We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Tiny Magnets Provide Breakthrough in Gene Therapy for Cancer

By Biotechdaily staff writers
Posted on 12 May 2008
A groundbreaking cancer treatment using microscopic magnets to enable ‘armed' human cells to target tumors has been developed. More...
A new study shows that inserting these nanomagnets into cells carrying genes to combat tumors, results in many more cells effectively reaching and invading cancerous tumors.

Using human cells as delivery vehicles for anticancer gene therapy has long been an appealing approach for treating tumors, but these cells typically reach tumors in insufficient numbers to effectively attack them. Now, a new ‘magnetic targeting' method has been developed to overcome this problem by Prof. Claire Lewis from the University of Sheffield (UK), Prof. Jon Dobson from the Keele University (UK), and Prof. Helen Byrne and Dr. Giles Richardson from the University of Nottingham (UK).

The technique involves inserting nanomagents into monocytes--a type of white blood cell used to carry gene therapy--and injecting the cells into the bloodstream. The researchers then placed a small magnet over the tumor to create a magnetic field and found that this attracted many more monocytes into the tumor.

The head of the laboratory in which the study was performed, Prof. Lewis, explained, "The use of nanoparticles to enhance the uptake of therapeutically armed cells by tumors could herald a new era in gene therapy--one in which delivery of the gene therapy vector to the diseased site is much more effective. This new technique could also be used to help deliver therapeutic genes in other diseases like arthritic joints or ischemic heart tissue.”

Prof. Dobson said, "Though the concept of magnetic targeting for drug and gene delivery has been around for decades, major technical hurdles have prevented its translation into a clinical therapy. By harnessing and enhancing the monocytes' innate targeting abilities, this technique offers great potential to overcome some of these barriers and bring the technology closer to the clinic.”

Prof. Nigel Brown, Biotechnology and Biological Sciences Research Council (BBSRC; Swindon, UK) director of science and technology, said, "This exciting work could have huge implications in healthcare. Fundamental bioscience research may sometimes seem to have little relevance to everyday life, but understanding the basic workings of the human body and harnessing nanoscale technology has resulted in a process of great potential in tumor therapy.”

The team of researchers is now looking at how effective magnetic targeting is at delivering a variety of different cancer-fighting genes, including ones which could halt the spread of tumors to other areas of the body.

This research was published online in the journal Gene Therapy April 17, 2008.


Related Links:
University of Sheffield
Keele University
University of Nottingham

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.